References

Overview of Baldness and its Prevalence

Baldness, also known as alopecia, refers to hair loss from the scalp or body, ranging from thinning hair to complete hair loss. It can be temporary or permanent and have various causes. Understanding its prevalence and contributing factors requires epidemiological and biostatistical approaches.

Prevalence of Baldness:

Prevalence refers to the proportion of a population with baldness at a specific time. Cross-sectional studies are useful for determining prevalence within a population at a specific point in time or over a defined period. Point prevalence measures the proportion at a single point in time, while period prevalence measures it over a period. Prevalence data is useful for conditions like baldness where the exact onset is hard to pinpoint or that last a long time. A baldness prevalence of 0.25 means 25% of the population has baldness at the time of measurement.

To understand the prevalence of baldness, research studies and statistics are essential. Data can be collected through observation, questionnaires, or medical records. Prevalence rates may vary depending on geographic location and ethnicity.

Factors Influencing Baldness:

Several factors can influence the development of baldness:

- **Genetics:** A family history of baldness is a significant risk factor. Androgenetic alopecia (male or female pattern baldness) is the most common type, a hereditary condition.
- **Hormones:** Hormonal imbalances, such as those occurring during menopause or pregnancy, can contribute to hair loss.
- **Medical Conditions:** Certain medical conditions, such as thyroid disorders or autoimmune diseases, can cause baldness.
- **Medications:** Some medications, such as chemotherapy drugs, can lead to temporary hair loss.
- **Stress:** High levels of stress can sometimes trigger hair loss.
- **Age:** The likelihood of experiencing hair loss increases with age and is a natural part of aging for many people.

Studying Baldness:

Epidemiological studies are conducted to understand the prevalence of baldness. These studies involve collecting data on the occurrence of baldness in different populations, considering factors like age, sex, genetics, and ethnicity. Epidemiologists use various study designs, such as cohort studies and case-control studies, to investigate the causes and progression of baldness. Biostatistical methods are used to analyze data from these studies, taking into account potential confounding factors and biases.

- **Observational Studies:** These studies observe and analyze existing data without intervention.
    - **Descriptive Studies:** These studies generate hypotheses about baldness. For example, a case report could detail a novel treatment response in a single patient, or

a case series could describe common characteristics among multiple individuals experiencing early-onset baldness.
    - **Analytic Studies:** These studies test hypotheses about associations between risk factors and baldness. A case-control study could compare a group with baldness to a control group without baldness to identify potential risk factors (e.g., family history, lifestyle factors).
- **Experimental Studies:** These studies involve interventions to test cause-and-effect relationships.
    - **Interventional Study:** This type of study could evaluate the effectiveness of a new treatment for baldness by comparing outcomes in a treatment group versus a control group.

Potential Biases in Observational Studies:

- **Selection Bias:** This occurs when the study sample doesn't accurately represent the target population.
- **Recall Bias:** This occurs when participants inaccurately remember past exposures or events.
- **Measurement Bias:** This results from systematic errors in data collection.
- **Survival Bias:** Prevalence is influenced by both the rate of new cases (incidence) and the duration of the condition.
- **Antecedent-Consequent Bias:** It can be difficult to determine if the exposure preceded the baldness, as both are assessed at the same time.
- **Migration Bias:** Individuals experiencing baldness might move away from an area perceived to contribute to the condition, skewing prevalence measures.

Important Considerations:

- **Causality:** Prevalence data makes it difficult to determine if a suspected cause comes *before* the baldness.
- **Time-Dependent Confounders:** These are covariates that act as both risk factors for the outcome (e.g., baldness) and predictors of subsequent treatments or exposures.
- **Confounding by Indication:** This occurs when the reason for receiving a treatment (e.g., medication for hair loss) is related to the outcome (e.g., hair growth).
- **Unmeasured Confounders:** Risk factors for baldness that are not measured in the study.

Practical Applications:

Cross-sectional studies can inform the planning and administration of preventive or healthcare services related to baldness (e.g., resource allocation for hair loss treatments). They can provide preliminary evidence for a causal relationship between certain exposures and baldness.

If you are concerned about hair loss, consult a dermatologist or hair loss specialist for diagnosis and treatment options. Identifying the underlying cause of baldness is crucial for effective management.

References:

- 1.pdf
- 2.pdf
- 3.pdf
- 4.pdf
- 6.pdf
- 7.pdf
- 8.pdf
- 9.pdf
- 10.pdf

- 11.pdf
- 12.pdf
- 13.pdf
- 14.pdf
- 15.pdf

Psychological and Social Impact of Hair Loss

Hair loss can significantly affect an individual's self-esteem, emotional well-being, and social interactions. Understanding these impacts is crucial for developing effective coping strategies and providing appropriate support.

Emotional and Psychological Effects:

Hair loss can trigger a range of negative emotions, including sadness, anxiety, frustration, anger, humiliation, depression, embarrassment, shock, and trauma. These feelings can lead to a lack of self-esteem, loss of confidence, and diminished relationships. Individuals may experience self-evaluative emotions like shame or reduced pride, recognizing these feelings as normal is the first step in managing them.

The distress caused by hair loss can sometimes mirror the emotional and behavioral responses seen in Non-Suicidal Self-Injury (NSSI), although hair loss itself is not NSSI. Understanding the functions of NSSI can provide insight into the distress caused by hair loss. These functions include:

- **Intrapersonal (Affect Regulation):** Managing emotional responses, escaping negative states (sadness, anxiety, anger), inducing positive states (calm, control), and self-punishment.
- **Interpersonal:** Communicating distress, seeking attention or support, and expressing anger towards others.

Individuals may also experience physical manifestations of emotional distress, such as sleeplessness, nightmares, loss of appetite and weight loss, headaches, forgetfulness, tearfulness, stomach and chest pains, hives and skin rashes, and even suicidal ideation and hopelessness.

Social Impact:

Hair loss can affect social interactions and self-perception, potentially leading to social anxiety, discomfort, and withdrawal from social activities. Individuals may experience challenges related to their identity and self-expression, as hair is often tied to one's sense of self. Cultural norms and expectations regarding hair can further influence the social impact. Negative feedback related to social interactions can also affect self-worth.

Coping Strategies and Interventions:

Several strategies can help individuals cope with the psychological and social impact of hair loss:

- **Self-Esteem Enhancement:** Focus on overall self-worth, independent of physical appearance. Challenge negative thoughts and replace them with positive and realistic ones.
- **Emotional Regulation:** Identify emotional triggers and the function they serve. Develop alternative coping strategies to regulate emotions and address needs. Practice stress-reduction techniques to minimize anxiety, guilt, or hostility.
- **Social Support:** Connect with friends, family, or support groups to share feelings and experiences. Seek support from others who understand.

- **Mindfulness:** Pay attention to the present moment without judgment. Observe thoughts and feelings about hair loss without getting carried away.
- **Distress Tolerance:** Tolerate distress without making things worse. Use distraction techniques, self-soothing activities, or acceptance strategies.
- **Interpersonal Effectiveness:** Assertively communicate needs and boundaries to others.
- **Self-Compassion:** Practice self-kindness and acceptance. Treat yourself with the same understanding and support you would offer a friend.
- **Cognitive Flexibility:** Challenge negative assumptions and beliefs about hair loss. Explore different ways to manage hair loss and seek new perspectives.
- **Values-Based Actions:** Focus on what's truly important (relationships, hobbies, career) and take actions aligned with those values.
- **Self-Disclosure:** Sharing experiences with hair loss can make others aware of your needs, potentially leading to increased perceived and enacted social support. Be mindful of the emotional tone of disclosures. Sharing positive aspects of your journey can boost well-being.

Adapting DBT Skills:

Dialectical Behavior Therapy (DBT) skills can be adapted to cope with hair loss distress:

- **Mindfulness:** Observe thoughts and feelings without judgment.
- **Emotion Regulation:** Identify and understand emotions related to hair loss. Increase positive emotions and decrease negative emotions.
- **Distress Tolerance:** Tolerate distress without making things worse.
- **Interpersonal Effectiveness:** Communicate needs and boundaries.

Observational Framework (Adapted from MSE):

Observing changes in appearance, behavior, mood, and affect can provide insights into the emotional impact of hair loss:

- **Appearance:** Note the condition of the hair, grooming habits, clothing choices, facial expressions, and eye contact.
- **Behavior:** Observe movements, posture, and attitude.
- **Mood:** Assess the person's overall emotional state.
- **Affect:** Observe the person's emotional expression.

Addressing Stigma:

Actively challenge negative stereotypes associated with hair loss. Promote acceptance and understanding of diverse appearances.

When to Seek Professional Help:

If hair loss is causing significant distress, impacting daily functioning, or leading to persistent negative emotions, consider seeking help from a therapist or counselor.

For Children and Families:

For children experiencing hair loss due to medical conditions like cancer, encourage open communication, promote self-esteem, and consider practical solutions like hats or wigs. Religious or spiritual coping mechanisms can also provide emotional comfort and support.

Genetic and Hormonal Factors in Androgenetic Alopecia

Androgenetic alopecia (AGA), the most prevalent form of hair loss, affects a significant portion of the global population, with estimates ranging from 60-70% in men and up to 50% in women. AGA, also known as male or female pattern baldness, is a common nonscarring hair loss with a strong hereditary component.

The pathogenesis of AGA involves the androgen receptor and dihydrotestosterone (DHT). DHT, converted from testosterone (T) by the enzyme 5α-reductase, binds to androgen receptors in susceptible hair follicles, forming a hormone-receptor complex. DHT exhibits a five-fold higher affinity for androgen receptors. This complex then activates genes responsible for the progressive miniaturization of hair follicles, resulting in reduced hair diameter, length, and pigmentation. Consequently, terminal follicles transform into vellus-like follicles with a shortened anagen phase, leading to the production of short and fine hair shafts. Inhibiting 5α-reductase has become a primary target in AGA treatment strategies. Genetic predisposition determines the age of onset for DHT production in hair follicles.

In women, AGA manifests as female pattern hair loss (FPHL), characterized by diffuse thinning over the crown region and mid-frontal scalp, while maintaining the frontal hairline (Ludwig pattern AGA). Conversely, men typically experience male pattern hair loss, involving bitemporal recession and vertex baldness. In women presenting with AGA, particularly younger individuals, an evaluation for underlying endocrine disorders such as polycystic ovary syndrome or late-onset congenital adrenal hyperplasia may be warranted. While lab testing is often not necessary, assessments of DHEA-S and total testosterone may be considered if features of hyperandrogenism are present. Scalp dermoscopy is a valuable tool for diagnosing and monitoring AGA, enabling the staging of severity and assessment of treatment response.

Research has explored the potential of plant extracts, such as those from *Serenoa repens* and *Pygeum africanum*, as 5α-reductase inhibitors. *In vitro* studies have demonstrated that *Serenoa repens* extracts, containing phytosterols like β-sitosterol and saponins, can inhibit both type I and type II 5α-reductase, leading to a decrease in 5α-DHT levels. Similarly, extracts from *Pygeum africanum* bark, containing triterpenes and phytosterols (primarily β-sitosterol), have also exhibited 5α-reductase inhibitory properties. *In vitro*, a lipid co-extract from both *Serenoa repens* and *Pygeum africanum* ("Complex Alphablok S") inhibited 5-alpha reductase activity by up to 68% in human scalp fibroblasts. Topical applications of zinc have demonstrated a reduction in the hair loss activity of 5-alpha-reductase type II. The amino acid L-lysine, prevalent in vegetable-rich diets common in Asian cultures, has been identified as a potential inhibitor of 5-alpha-reductase type II, offering a possible explanation for the lower incidence of male pattern baldness in these populations.

DNA methyltransferase 1 (DNMT1), an epigenetic modulator, plays a role in hair follicle regeneration. Studies using mice with a K14-Cre-mediated loss of DNMT1 in the epidermis showed that DNMT1 is expressed in the developing skin and cycling hair follicles, particularly in the basal epidermal layer and hair germs/pegs during embryonic development, and in the outer root sheath (ORS), inner root sheath, and matrix of adult anagen hair follicles (62.pdf). Mutant mice exhibited progressive alopecia, with hair density decreasing significantly (62.pdf). Hair size, both diameter and length, was significantly reduced in all hair types (62.pdf). The study also observed increased expression of intracisternal A particle (IAP), normally silenced by methylation, in the ORS and hair matrix of the mutant mice, along with a reduction in 5-methylcytosine-positive cells, indicating DNA hypomethylation (62.pdf). These results highlight the importance of DNA methylation in maintaining stem cell homeostasis during the development and regeneration of ectodermal organs (62.pdf).

Other Causes of Hair Loss: Alopecia Areata, Telogen Effluvium

Other Causes of Hair Loss: Alopecia Areata and Telogen Effluvium

Alopecia areata and telogen effluvium are non-scarring forms of hair loss. Alopecia areata is an autoimmune disease characterized by a sudden onset and unpredictable course, resulting in non-scarring hair loss that can affect any hair-bearing area. The pathogenesis involves a T lymphocyte-mediated attack on hair follicles. Clinically, it presents as round patches of hair loss and may affect eyebrows, eyelashes, and body hair. Hair regrowth is often initially white or gray. Diagnostic considerations include obtaining TSH, ANA, RF, Ferritin, TTG, and HbA1c levels. Management strategies include topical steroids, intralesional steroids, oral steroids, topical immunotherapy, immunosuppressants, and Janus kinase (JAK) inhibitors. A systematic review indicates a higher incidence of anxiety, depression, ADHD, paranoia, and OCD, particularly concerning relapse, among affected individuals. Reports of suicidal ideation (12.8%) and suicide have been documented in patients with alopecia areata. Alopecia areata and telogen effluvium are notable mimickers of lupus non-specific manifestations and are listed as differential diagnoses for alopecia, which can be a symptom associated with lupus.

Telogen effluvium is a common form of hair loss characterized by an increased proportion of hairs in the telogen (shedding) phase. Normally, approximately 90% of hairs are in the anagen (growth) phase and 10% in the telogen phase; in individuals with telogen effluvium, these proportions shift to approximately 80% and 20%, respectively. This premature transition results in accelerated hair shedding. Numerous triggers can induce telogen effluvium, including emotional or psychological stressors, systemic illnesses, hormonal changes, surgery, medication changes, dietary alterations or abrupt weight loss, and nutritional deficiencies. It is the most common alopecia associated with systemic illness. Medications frequently implicated include acitretin, isotretinoin, beta blockers, captopril, antidepressants, anticonvulsants, diabetic drugs, and oral contraceptives. The interval between the inciting event or agent and the onset of shedding is typically weeks to a few months. Patients typically report an increase in hair shedding, which may persist for 6-12 months; a chronic form, though less common, can persist for years. Examination reveals diffuse thinning across the scalp. A gentle pull test, involving gentle traction on 10-20 hairs, typically yields approximately 10 hairs, with normally only 1-2 hairs coming out with a white bulb. Diagnostic evaluation includes a thorough drug history and detailed history gathering related to stressful events, life changes, diet changes, or medical issues preceding the onset of hair loss. Ferritin and thyroid-stimulating hormone (TSH) testing should be considered. Management primarily involves reassurance, addressing any nutritional deficiencies, and discontinuing any culprit drugs, addressing underlying medical problems, or mitigating persistent stressors. Topical minoxidil 5% foam or solution may be considered, and severe or persistent cases may benefit from oral minoxidil.

Isotretinoin (ISO), an effective treatment for acne, is associated with potential adverse effects, including hair loss, most commonly telogen effluvium. A retrospective analysis investigated the association between isotretinoin and alopecia, reviewing patients diagnosed with hair loss between 2013 and 2018 and comparing them to isotretinoin users without hair loss. The study identified 48 patients with hair loss who had been prescribed isotretinoin. Of these, 19 (39.6%) experienced hair loss concurrently or within two years of isotretinoin treatment. Among these 19 patients, 8 (42%) were diagnosed with telogen effluvium, and 5 (26%) presented with androgenetic alopecia, sometimes co-occurring with telogen effluvium. Two patients were diagnosed with alopecia areata. Compared to isotretinoin users without hair loss, those who developed hair loss were significantly older ($p = 0.008$), had received higher cumulative isotretinoin doses ($p = 0.004$), and had longer treatment durations ($p < 0.001$).

A thesis submitted by Anissa Mulia Damayanti at Universitas Pelita Harapan in 2022, investigates the correlation between stress levels and the incidence of TE among medical students. The paper contributes to the understanding of TE by examining its potential association with stress in a specific population (medical students), a group known for experiencing high levels of academic and personal pressure.

The telogen phase is the resting phase of hair growth, characterized by a lack of living cells and natural shedding. Hair in the telogen phase is less likely to contain root tissue, making nuclear DNA analysis inconsistent and necessitating mitochondrial DNA analysis. This distinction is crucial because telogen effluvium involves premature or excessive shedding of hair during the telogen phase. The anagen phase, the active growth phase involving living cells, where hair is more likely to contain root tissue suitable for nuclear DNA analysis. Understanding these phases is fundamental to differentiating between normal hair shedding and pathological conditions like telogen effluvium.

References

- 49.pdf
- 47.pdf
- 46.pdf
- 44.pdf
- 43.pdf
- 42.pdf
- 41.pdf
- 40.pdf
- 39.pdf
- 38.pdf
- 37.pdf
- 36.pdf
- 35.pdf
- Tran, Evron, & Goh, 2023

Mechanism of Action of Existing Treatments

Current baldness treatments, particularly those targeting hormonal pathways, primarily function by modulating steroid hormone action. Steroid hormones diffuse into cells and interact with cytoplasmic or nuclear receptors. The resulting hormone-receptor complex binds to DNA, regulating gene transcription and subsequent protein synthesis, a process known as the genomic action of steroid hormones.

The androgen receptor (AR) is a key target, given the role of androgens in hair follicle miniaturization. The AR belongs to the nuclear hormone receptor superfamily, which includes estrogen receptor (ER), progesterone receptor (PR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). These receptors share a ligand-binding domain (LBD) and a DNA-binding domain (DBD). Ligand binding to the LBD induces a conformational change, facilitating dimerization and binding to specific DNA sequences. In the case of the AR, this binding leads to the transcription of genes involved in androgen-dependent processes. Treatments often act as antagonists, preventing androgen binding and reducing the expression of these genes.

Steroid hormone receptor action is also modulated by coregulatory proteins, including coactivators (e.g., SRC-1, GRIP-1) and corepressors (e.g., NCoR, SMRT). These proteins interact with the receptor complex to either enhance or repress transcription. The specific complement of coregulatory proteins influences the response to hormone treatment, leading to tissue-selective

effects. Selective estrogen receptor modulators (SERMs) like tamoxifen exemplify this, acting as antagonists in breast tissue but agonists in bone.

In addition to genomic actions, steroid hormones can exert non-genomic effects via protein-protein interactions with membrane-bound receptors and other membrane proteins, leading to rapid cellular responses. While the precise role of non-genomic actions in baldness treatments is less well-defined, they represent an additional layer of complexity.

For androgenetic alopecia (AGA), the most common cause of hair loss, treatments aim to halt the progression of hair loss by targeting various aspects of the process.

Finasteride (1mg daily for males, 2.5-5mg for females) is a type 2 5-alpha reductase inhibitor, reducing the conversion of testosterone to DHT by up to 70%. By lowering DHT levels, finasteride mitigates the androgen-mediated miniaturization of hair follicles.

Dutasteride (0.5mg three times per week or once daily) inhibits both type 1 and type 2 5-alpha reductase, resulting in a more significant reduction in DHT levels (up to 90%) compared to finasteride.

Minoxidil topical (5%) increases hair density and reduces shedding. While the precise mechanism of action remains unclear, it is believed to stimulate hair growth by prolonging the anagen phase. Low-dose oral minoxidil is also utilized, with common side effects including unwanted hair growth.

Spironolactone (50-200mg daily) is employed in females to improve follicular density. It functions as an antiandrogen.

Low-Level Light Therapy (LLLT) devices, emitting light at 630-670nm, are used to stimulate hair growth. The mechanism may involve stimulation of mitochondria and the generation of reactive oxygen species and antioxidants, potentially prolonging the anagen phase and inhibiting the catagen phase.

Platelet-Rich Plasma (PRP) involves injecting a concentrated solution of platelets derived from the patient's own blood into the scalp. The growth factors contained within platelets are thought to promote hair growth.

For alopecia areata, an autoimmune disease, the primary mechanism involves a T lymphocyte-mediated attack on hair follicles. Management strategies include topical and intralesional steroids to suppress the immune response, as well as topical immunotherapy, immunosuppressants, and Janus kinase (JAK) inhibitors.

In central centrifugal cicatricial alopecia (CCCA), management focuses on halting inflammation and preventing further scarring with topical and intralesional steroids, topical minoxidil, oral antibiotics, antimalarials, and topical metformin.

Telogen effluvium is characterized by a premature transition of hairs to the telogen phase, leading to increased shedding. Management involves addressing underlying causes such as nutritional deficiencies, culprit drugs, medical problems, or stressors. Topical minoxidil 5% may also be considered.

Traction alopecia, resulting from prolonged tension on hair shafts, is managed by avoiding tight hairstyles. Topical steroids, topical 5% minoxidil, oral antibiotics (for anti-inflammatory effects), and intralesional steroids may also be used.

Lichen planopilaris (LPP) is thought to be caused by dysfunction in cell-mediated immunity. Management aims to halt the inflammatory process and minimize scarring with topical steroids, intralesional steroids, hydroxychloroquine, antibiotics, and immunosuppressants.

Treatments aimed at promoting hair growth often target the anagen phase, seeking to prolong its duration or stimulate activity within hair follicles. Treatments might also target the regulation of DNase1L2 to influence the structural integrity and growth of hair. Personalized approaches, considering individual genetic factors affecting DNA degradation, might be necessary for optimizing treatment efficacy.

Oral and topical retinoids have been reported as potentially helpful and used by some as a treatment for frontal fibrosing alopecia and lichen planopilaris.

Topical Treatments: Minoxidil and its Variations

Topical Treatments: Minoxidil and its Variations

Minoxidil, initially developed as an oral vasodilator for hypertension, unexpectedly demonstrated hypertrichosis in over 80% of users, prompting research into its topical application for hair regrowth.

Efficacy:

Early clinical observations revealed hair regrowth in individuals with male pattern baldness treated with oral minoxidil. Subsequent open-label studies assessing topical 5% minoxidil in patients with alopecia areata and androgenetica indicated hair growth stimulation, ranging from minimal to significant restoration, typically within 3-8 months. One study reported hair growth induction in 80.8% of alopecia areata patients after 6 months of twice-daily topical 1% minoxidil application, with 16 achieving acceptable terminal hair growth. However, a double-blind study comparing topical 1% or 5% minoxidil to a vehicle control in men with pattern baldness showed only a minimal increase in mean hair length across all groups, including the placebo, with no statistically significant differences during the 12-week treatment period.

Methodology:

Clinical studies have employed varying concentrations of topical minoxidil (1%, 3%, 5%) in propylene glycol-ethanol-water vehicles, applied once or twice daily, with or without occlusion. Hair growth was assessed through visual observation and measurement of hair length. Systemic absorption was evaluated via radioimmunoassay to measure serum minoxidil levels. Percutaneous absorption studies in rats and monkeys utilized 14C-minoxidil to quantify the percentage of the applied dose excreted in urine and stool.

Limitations and Safety:

Dermal acute toxicity studies in rats indicated slight toxicity at higher doses (30 mg/rat/day and 60 mg/rat/day), with observed dose-related decreases in hemoglobin and erythrocyte counts, and alterations in serum sodium, chloride, and cholesterol levels. In the double-blind study, mild stinging, burning, itching, and erythema were reported in some subjects, attributed to the vehicle rather than minoxidil itself. Systemic absorption of topical minoxidil was generally low, with serum levels ranging from undetectable to a maximum of 6.2 ng/ml in clinical trials. Percutaneous absorption studies in animals showed that a significant portion of the applied dose remained in the skin at the application site.

Considerations for Future Research:

The study of bakuchiol and retinol as topical treatments for photoaging provides a framework for evaluating minoxidil. Randomized, double-blind studies with objective measurements (e.g., wrinkle surface area, hyperpigmentation using systems like the BTBP 3D Clarity Pro ® Facial Modeling and Analysis System) and subjective tolerability assessments are crucial. Comparative studies evaluating different minoxidil variations (e.g., concentrations, formulations) against each other or established treatments are valuable. Evaluating both efficacy and tolerability, as demonstrated by the bakuchiol/retinol study (where retinol users reported more scaling and stinging), is essential.

Other Topical Treatments (Contextual Information):

Aminosalicylates (5-ASA) are used topically in the gastrointestinal tract to reduce bowel inflammation, particularly in ulcerative colitis for both induction and maintenance of remission. However, their efficacy in Crohn's disease remains unclear. Topical steroids, available in varying strengths, are used to mitigate inflammation and pruritus associated with eczema. Prolonged use of high-potency topical steroids can induce adverse effects, including skin thinning and systemic absorption. Topical retinoids may possess therapeutic benefits for specific alopecia subtypes.

References

- 49.pdf (49.pdf)

Oral Medications: Finasteride and Dutasteride

Finasteride and dutasteride are oral 5-alpha reductase inhibitors (5-ARIs) used to treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and androgenic alopecia (male pattern hair loss). These medications reduce prostate volume by blocking the conversion of testosterone to dihydrotestosterone (DHT). Finasteride (5mg daily) selectively inhibits type 2 5-AR, while dutasteride (0.5mg daily) inhibits both type 1 and type 2 isoenzymes. Prostate volume typically decreases by approximately 25% within six to twelve months, leading to a reduction in prostate-specific antigen (PSA) levels by roughly 50%. The rationale for using 5-ARIs is based on the observation that prostate volume increases by an average of 3.5% to 5% annually in men with BPH over 50 years of age.

Efficacy in BPH/LUTS:

Finasteride has demonstrated efficacy in improving urinary flow and alleviating BPH symptoms over several months. Clinical data suggests that finasteride reduces the risk of acute urinary retention and the subsequent need for surgical intervention. A treatment duration of six months or longer may be required to assess the drug's effectiveness in individual cases. While both medications exhibit comparable efficacy, individual responses vary, and some patients may not experience noticeable improvements in urinary flow or symptom relief despite prostate shrinkage.

Monotherapy with 5-ARIs was initially considered sufficient; however, studies have demonstrated improved outcomes with combination therapy involving an alpha-blocker (AB) and a 5-ARI. Current clinical practice suggests initiating combination therapy for patients with enlarged prostates and maintaining this regimen. The concurrent use of an AB can provide initial symptom relief while awaiting the effects of the 5-ARI, which may take three to six months to demonstrate efficacy, unlike ABs, which produce results within two to four weeks. Patients should be educated on managing potential symptom exacerbation during combination therapy. Lack of response to combination therapy may indicate a prostate refractory to treatment or the presence of overactive bladder (OAB).

A systematic review of clinical trials revealed that finasteride had a moderate effect on reducing prostate volume and a significant effect on IPSS score and Qmax.

Potential in Prostate Cancer:

Finasteride and dutasteride have been investigated for their potential in prostate cancer prevention and treatment. The Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial demonstrated that finasteride and dutasteride decreased prostate cancer prevalence by 24.8% and 23%, respectively. However, these trials also reported an increased incidence of high-grade tumors in patients treated with these medications. One study concluded that dutasteride, but not finasteride, may have therapeutic potential for prostate cancer.

Limitations and Side Effects:

The use of finasteride and dutasteride is associated with potential side effects, including diminished ejaculatory volume, erectile dysfunction (impotence), decreased libido, and gynecomastia (breast enlargement and/or tenderness). Allergic reactions, including rash, itching, hives, and swelling of the lips and face, are possible. Testicular pain has been reported, albeit rarely. While the decrease in semen volume does not typically impair sexual function, these side effects can impact patient compliance.

Long-term safety has been subject to scrutiny, with adverse events, particularly sexual dysfunction, reported for two decades. Associations between finasteride use and depressive symptoms, including suicidal ideation, have been observed, especially among individuals experiencing persistent sexual adverse events, leading to the recognition of post-finasteride syndrome. Regulatory agencies have issued warnings regarding these adverse events.

A meta-analysis indicated that the overall risk of depression after 5-ARI use was not significantly high, but its clinical importance warrants further investigation. Sensitivity analysis indicated a significant increase in hazard ratio with age.

Important Considerations:

Patients undergoing finasteride treatment require regular medical checkups. Finasteride can alter prostate-specific antigen (PSA) values, necessitating careful interpretation of PSA results in prostate cancer screening. Finasteride is contraindicated for use in women, particularly those who are or may become pregnant, due to the risk of causing abnormalities in the sex organs of a developing male fetus. The tablets are coated to prevent contact with the active ingredient during normal handling, provided they are not broken or crushed.

The decision to implement 5-ARI monotherapy should be carefully evaluated due to potential adverse effects, including erectile dysfunction, decreased libido, and gynecomastia. Furthermore, some studies suggest a correlation between 5-ARI administration and a possible risk for suicidal attempts and depression. (61.pdf)

References:

- 65.pdf
- 63.pdf
- 62.pdf
- 61.pdf
- 60.pdf
- 59.pdf

- 58.pdf
- 57.pdf
- 56.pdf
- 55.pdf
- 54.pdf
- 53.pdf
- 52.pdf
- 51.pdf

Surgical Options: Hair Transplantation Techniques

Current Treatment Options: Efficacy and Limitations

Surgical Options: Hair Transplantation Techniques

Surgical hair restoration relies on techniques like Follicular Unit Transplantation (FUT) and Follicular Unit Extraction (FUE). Mastering these techniques, including donor harvesting, recipient site creation, graft dissection, and graft placement, is essential for successful outcomes. Hands-on training through cadaver workshops and training models is considered crucial. Enhanced learning experiences integrate high-definition 3D and 2D lectures with live surgical dissections. Critical thinking and quality control during graft preparation and placement are instrumental for achieving consistent results.

Follicular Unit Extraction (FUE):

- **Description:** FUE is a method of hair transplantation.

The International Society of Hair Restoration Surgery (ISHRS) promotes high standards in medical practice and research, offering continuing medical education for hair transplant surgeons. While surgery is a viable treatment option for some conditions, such as Benign Prostatic Hyperplasia (BPH), the optimal surgical procedure depends on the patient's specific symptoms and overall medical condition.

Low-Level Laser Therapy (LLLT) for Hair Growth

Low-Level Laser Therapy (LLLT) for Hair Growth: Efficacy and Limitations

Introduction

Laser therapy, also known as photobiomodulation (PBM), is a medical technique that uses laser light to stimulate tissue growth and healing. Its applications include the treatment of musculoskeletal conditions and, potentially, hair growth. This document reviews the effectiveness of LLLT for hair growth, addressing its mechanisms, clinical applications, and limitations.

Efficacy of LLLT in Musculoskeletal Conditions

Strong evidence supports the use of laser therapy for musculoskeletal conditions. It can effectively reduce pain, accelerate healing in soft tissue and bony structures, and decrease inflammation. Laser therapy may serve as an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs) and potentially mitigate the effects of interleukin-1 (IL-1). It benefits both acute and chronic musculoskeletal conditions, including rheumatoid arthritis, by promoting angiogenesis and blood flow through stimulating new blood vessel capillary budding and increasing collateral circulation.

While laser therapy is considered more effective than ultrasound or infrared therapy, its benefits can be enhanced when used in conjunction with exercise therapy.

Mechanism of Action

LLLT exerts its effects through photochemical mechanisms. PBM involves the interaction of coherent light (photons) with tissue. A primary effect of PBM is the absorption of photons by chromophores, particularly cytochrome-C oxidase in the electron transport chain within mitochondria. This process is hypothesized to increase ATP production, oxygen consumption, and modulate reactive oxygen species (ROS) production. Alternative photoacceptors, such as cellular membranes, ion channels, porphyrins, and flavoproteins, have also been proposed, suggesting a complex interplay of multiple reactions.

LLLT has demonstrated potential in reducing pain, joint inflammation, and muscle spasms, as well as stimulating tissue repair. The clinical benefits may include temporary analgesia via neural blockade, resolution of inflammation, and improved regeneration of healing tissue.

Laser Parameters and Classifications

Lasers are classified based on their wattage, ranging from Class I (microwatts) to Class IV (exceeding 500 milliwatts). Class III lasers are further divided into Class IIIa (up to 5 milliwatts) and Class IIIb (up to 500 milliwatts). Class III lasers, particularly Class IIIb, are utilized in the treatment of musculoskeletal conditions. Class IV lasers are employed in both thermal (surgical) and photochemical applications. Class III lasers, often referred to as "cold lasers," do not generate significant heat and are considered safer for prolonged use. In contrast, Class IV lasers produce heat and require careful monitoring to prevent tissue damage or burns.

LLLT typically utilizes light from low to mid-power lasers or light-emitting diodes (LEDs) within the visible red to near-infrared (NIR) spectrum (600-1000 nm). Power outputs generally range from 1-500 mW, delivering an average power density (irradiance) between 1 mW/cm^2 and 5 W/cm^2. The study utilized multiple laser devices, including 810nm 200mW, 810mW 1W, and 660 nm and 850nm LED 1390mW aggregate, targeting specific clinical effects.

A critical factor influencing LLLT efficacy is the biphasic dose response, which correlates with the wavelength and energy density absorbed by the target chromophore. Furthermore, the use of pulsed light, particularly superpulsed lasers, has shown potential advantages in penetrating melanin and other skin barriers, enabling deeper tissue penetration compared to continuous wave (CW) lasers. Superpulsed infrared laser technology has demonstrated therapeutic efficacy at depths of up to 10 cm, potentially benefiting target tissues such as bones, tendons, ligaments, and cartilage.

Limitations and Contraindications

While laser therapy demonstrates efficacy, it is not without limitations and contraindications. When used with adequate precautions, its benefits outweigh the potential harmful side effects. Despite numerous reports of positive findings, inconsistencies in light sources, treatment protocols (including wavelength, fluence, power density, and pulse structure), and study methodologies have contributed to conflicting results and controversies surrounding LLLT. A lack of comprehensive reporting of light parameters in some studies has also hindered reproducibility and further research. Therefore, rigorous scientific methodology and detailed specification of light source characteristics are crucial for generating reliable and useful data.

Adjunctive Treatment

Laser therapy, presumably including LLLT, is considered a relevant, albeit potentially adjunctive, treatment modality within the broader context of hair restoration.

References

- 73.pdf
- 72.pdf
- 71.pdf
- 70.pdf
- 69.pdf
- 67.pdf
- 66.pdf
- 65.pdf
- 63.pdf
- 62.pdf
- 61.pdf
- 60.pdf
- 59.pdf

Stem Cell Therapy and Regenerative Medicine

Stem Cell Therapy and Regenerative Medicine: Emerging Therapies and Future Directions

This document explores emerging therapies and future directions within stem cell therapy and regenerative medicine, encompassing diverse applications from skin regeneration to musculoskeletal conditions and hair restoration.

I. Therapeutic Reprogramming and Skin Regeneration

Dr. Anthony Oro's research focuses on leveraging the skin as a model for Precision Health. His team pioneers "Therapeutic Reprogramming" for epidermolysis bullosa, a rare blistering skin disease. This involves converting adult stem cells from patients into induced pluripotent stem cells (iPSCs), correcting the disease-causing genetic code using CRISPR technology, and growing healthy cells in vitro. These corrected cells are then engineered into skin grafts for repairing diseased tissue. The Center for Curative and Definitive Medicine, co-directed by Dr. Oro, aims to scale up and expand the application of corrected, iPSC-derived therapies to provide personalized treatments for genetic diseases. This initiative utilizes the Stanford Laboratory for Cell and Gene Medicine, a facility adhering to FDA's Current Good Manufacturing Practice standards for cell and gene therapy production. Beyond genetic disorders, Dr. Oro's team is engineering "functionalized" tissue, incorporating pigment, sweat glands, and hair follicles, to address a broader range of disorders. The department's vertically integrated program facilitates the translation of laboratory findings directly into clinical applications.

II. Laser Therapy for Musculoskeletal Conditions

Laser therapy, or photobiomodulation, enhances tissue growth and healing, gaining popularity in treating musculoskeletal conditions. Classifications include Low-Level Laser Therapy (LLLT) and High-Power Laser Therapy (HPLT), categorized by wattage according to ANSI Laser Standard Classifications. Class III lasers (up to 500 milliwatts) are considered safe, while Class IV lasers require careful monitoring to prevent tissue damage. Research indicates that laser therapy decreases

pain and accelerates healing in soft tissue and bony structures, reduces inflammation, and promotes angiogenesis and blood flow by stimulating new blood vessel capillary budding and increased collateral circulation. While contraindications exist, the benefits of laser therapy, when used with appropriate precautions, generally outweigh potential harmful side effects, supporting its safety and efficacy in treating musculoskeletal conditions.

III. LLLT for Temporomandibular Disorder (TMD)

A randomized, blinded, controlled clinical evaluation investigated the clinical efficacy of Low Level Laser Therapy (LLLT) as an initial pain reduction therapy for patients with chronic Temporomandibular Disorder (TMD). Twenty-nine patients were treated with either active or sham laser therapy. Multiple laser devices were utilized, including 810nm 200mw, 810mw 1W, and 660 nm and 850nm LED 1390mw aggregate, applied to tender points and selected anatomic points, targeting specific clinical effects. Each subject received five treatments within a 2-3 week period. Results indicated a significant improvement in the active treatment group, with a mean VAS score improvement of 36.93 from a baseline mean of 59.46, compared to an improvement of 10.23 from a baseline mean of 55.7 in the sham placebo therapy group ($p<.001$). Significant improvements were also observed in the active group compared to the control group in SF-36 physical scores (SF-36PCS) ($p<.001$) and SF-36 mental scores (SF-36 MCS) ($p<.047$). The study concluded that LLLT, using the specified parameters, was effective in significantly reducing short-term pain (measured two weeks post-treatment) in patients with chronic TMD pain. The proposed mechanism of action for LLLT involves photobiomodulation, where photons are absorbed by chromophores, particularly cytochrome-C oxidase in the electron transport chain, affecting various tissues involved in chronic head and neck pain. The clinical benefits may include temporary analgesia via neural blockade, resolution of inflammation, and improved regeneration of healing tissue.

IV. Mechanisms and Applications of Low-Level Laser (Light) Therapy (LLLT)

Low-level laser (light) therapy (LLLT), or photobiomodulation, is a drug-free, non-invasive approach to promote tissue regeneration and healing. It utilizes low to mid-power lasers or light-emitting diodes (LEDs) within a specific power output range (1-500 mW) and a narrow spectral range (600-1000 nm). The mechanism involves light absorption by chromophores or photoacceptors, leading to a biphasic dose response. Mitochondria are considered primary sites for the initial effects of LLLT, influencing cellular signaling and second messenger pathways. A key molecular process is hypothesized to be the photodissociation of inhibitory nitric oxide (NO) from cytochrome c oxidase, potentially increasing ATP production and modulating reactive oxygen species. Pulsed light modalities in LLLT demonstrate distinct biological and clinical effects compared to continuous wave (CW) light. Pulsed wave operation may enhance penetration through melanin and other skin barriers, facilitating access to deeper target tissues. Superpulsed infrared laser technology has shown therapeutic efficacy at depths up to 10 cm, benefiting tissues such as bones, tendons, ligaments, and cartilage. Recent advancements highlight LLLT's immunoregulatory and neuroprotective properties, along with its preferential action on stem cells and progenitor cells. Future therapeutic strategies may involve multiple wavelengths targeting different inflammatory mechanisms. The "pain, inflammation, and immune response (PII) axis" is a critical area of investigation.

V. Surveillance Methodologies for Emerging Therapies

Surveillance, defined as the continual observation of a person or group, monitoring behavior, activities, or changing information for the purpose of influencing, managing, directing, or protecting, is applicable to tracking outcomes and potential adverse events associated with emerging therapies like stem cell therapy and regenerative medicine. The rationales for conducting

surveillance are directly applicable to stem cell therapy and regenerative medicine: Determine Baseline (Endemic), Early Detection of Epidemics (Adverse Outcomes), Assess the Effectiveness of Prevention and Control Measures, Monitor the Occurrence of Adverse Outcomes to Identify Risk Factors, Observe Practices to Promote Compliance, and Target Performance Improvement. The NHSN model could be adapted to create a similar network for monitoring the safety and efficacy of stem cell therapy and regenerative medicine. In the context of stem cell therapy and regenerative medicine, a combination approach may be most appropriate, involving Targeted Surveillance and Concurrent Monitoring.

VI. Hairdressing in Ghana: A Socio-Cultural Perspective (Tangential Relevance)

Hairdressing in Ghana during the 20th century served as a site for debates concerning identity, belonging, and nationhood. Hairdressing served as a symbolic system for expressing national identity, reflecting intellectual, socio-cultural, and economic practices through which men and women fashioned citizenship. The media played a crucial role in showcasing hairdressers' work, critiquing hairstyles, and promoting skill training and professional associations. Between 1920 and 1970, hairdressing contributed to shaping gender and age-based identities in urban areas. Hairdressers participated in state and national ceremonies, becoming visual icons of "cultural nationalism," "African Nationalism," "African pride," and Pan-Africanism. During the economic challenges of the 1970s and 1980s, the informal economy, including hairdressing, became increasingly important. The Ghana Hairdressers and Beauticians Association (GHABA) gained technical assistance from the Industrial and Commercial Unit (ICU) to negotiate with governmental and non-governmental bodies for skill training and support for their microfinance businesses.

VII. Demineralized Dentine Graft for Socket Preservation

Demineralized dentine matrix contains growth factors that can stimulate bone regeneration. The use of demineralized dentine graft represents a regenerative approach to enhance bone healing and preserve alveolar ridge dimensions following tooth extraction. The methodology likely involved clinical observation and radiographic assessment of socket healing following the application of the graft material. The findings contribute to the broader field of regenerative medicine by exploring alternative biomaterials to promote tissue regeneration in the oral and maxillofacial region.

VIII. PRP Therapy in Hair Restoration

The course curriculum includes "PRP, Laser, Etc.," indicating the incorporation of PRP therapy as an adjunct to surgical hair restoration. Its inclusion suggests a recognized role for PRP in potentially enhancing graft survival, promoting wound healing, or stimulating hair growth.

IX. Finasteride and Regenerative Medicine for BPH

Finasteride functions by lowering levels of dihydrotestosterone (DHT), leading to a shrinkage of the enlarged prostate gland in a majority of men, potentially resulting in gradual improvements in urinary flow and associated symptoms. The limitations of Finasteride in achieving complete and sustained remission of BPH symptoms create an opportunity for regenerative medicine approaches, including stem cell therapy. Stem cell-based therapies could potentially offer a more targeted and regenerative approach to BPH by Regenerating Damaged Tissue, Modulating the Cellular Microenvironment, and Targeting the Underlying Causes of BPH.

X. Finasteride and Dutasteride Studies in Prostate Cancer

Dutasteride, which inhibits both 5αR1 and 5αR2, demonstrated a more pronounced effect on inhibiting prostatic intraepithelial neoplasia (PIN) progression and prostate cancer development

compared to finasteride, which only inhibits 5αR2. The post-dutasteride group exhibited improved outcomes compared to the pre-dutasteride group, which paradoxically showed an increased incidence of high-grade carcinoma. Conversely, finasteride diets showed little benefit and, in some instances, increased the incidence of high-grade carcinoma. The study concludes that dutasteride may have therapeutic potential in managing prostate cancer progression, while finasteride appears less effective and potentially detrimental.

XI. 5-ARIs and Hair Follicle Regeneration

5-ARIs promote the regeneration of hair follicles in the treatment of male pattern hair loss (MPHL). Specifically, the mechanism of action involves blocking the conversion of testosterone to dihydrotestosterone, which reduces prostate volume in BPH/LUTS and promotes hair follicle regeneration in MPHL.

XII. Finasteride Monotherapy for Benign Prostatic Hyperplasia

The review demonstrated significant clinical benefits associated with finasteride monotherapy. The effect of finasteride on reducing prostate volume (PV) was moderate, with a standardized mean difference (SMD) effect between 0.5 and 0.8 across evaluable trials. The impact on IPSS score and Qmax was considered significant, with SMD values ranging from 0.2 to 0.5. While no severe adverse events or psychiatric disorders were reported, sexual health dysfunctions were significantly more prevalent in patients treated with finasteride compared to those receiving placebo.

Platelet-Rich Plasma (PRP) Therapy for Hair Loss

Platelet-Rich Plasma (PRP) Therapy for Hair Loss: Current Evidence and Future Directions

Platelet-Rich Plasma (PRP) therapy is emerging as a potential treatment for hair loss, leveraging the regenerative properties of concentrated platelets derived from the patient's own blood. PRP preparation involves a two-stage centrifugation process. Initially, a slow-speed centrifugation separates red blood cells, allowing collection of plasma containing platelets and white blood cells (WBCs). Subsequently, a higher-speed centrifugation concentrates the platelets, aiming for a concentration greater than 1000 x 10^3 platelets/μl, approximately a five-fold increase. Adjusting centrifugation speed and plasma volume can control platelet concentration and WBC exclusion. While commercial systems offer standardized protocols, inconsistencies in PRP product generation have been observed.

The rationale for PRP therapy lies in the abundance of growth factors within platelet alpha granules, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and vascular endothelial growth factor (VEGF). These growth factors stimulate reparative activities of host cells at the administration site, exceeding endogenous responses. Platelets contain over 30 bioactive proteins, including epidermal growth factor (EGF), fibroblastic growth factor (FGF), connective tissue growth factor (CTGF), and insulin-like growth factor (IGF-1), crucial for hemostasis and tissue healing.

PRP injections are utilized in the treatment of tendinopathy and arthritis. The injection procedure involves administering a local anesthetic, followed by the PRP injection, often guided by ultrasound imaging. Post-injection care includes ice application. The procedure lasts 45-60 minutes. Patients should discontinue NSAIDs seven days prior. PRP is not indicated for back or neck injuries.

PRP, a first-generation platelet concentrate introduced in 1997, has been more extensively studied than Platelet-Rich Fibrin (PRF). PRP preparation involves drawing whole blood into acid citrate dextrose tubes, followed by centrifugation using a soft spin for 10 minutes.

A key advantage of PRP therapy is its autologous nature, minimizing the risk of allergic reactions or rejection. Clinical observations suggest noticeable hair regrowth within a few months. A study reported a 93% regrowth beyond baseline after monthly injections over four months. Individual outcomes may vary, necessitating a thorough patient history and review of exclusion criteria. Repeated monthly injections, potentially supplemented by topical and/or oral treatments, are typically recommended. Frequent initial injections followed by long-term maintenance injections may be necessary for chronic hair loss. The procedure is generally safe, with minimal discomfort, performed using a small needle by a board-certified dermatologist.

Challenges in Efficacy Assessment and Standardization

Assessing PRP's efficacy is challenging due to inconsistencies in PRP preparation and administration across studies. Variables include platelet activation (degranulation and release of bioactive factors), activation methods (freeze/thawing, thrombin, or calcium re-supplementation), and the form of PRP administered (soluble, clotted gel, or liquid releasate). There is no clear correlation between platelet concentration and growth factor concentrations. Variations in PRP preparation, activation, and administration protocols may contribute to inconsistent clinical outcomes. Optimizing PRP preparation methods, identifying the optimal platelet concentration and composition (e.g., leucocyte-rich vs. leucocyte-poor), and establishing standardized treatment protocols for hair loss are needed. The inconsistent correlation between platelet concentration and growth factor levels warrants investigation into the specific growth factors and other bioactive molecules responsible for promoting hair growth.

Antimicrobial Properties and Scalp Health

PRP exhibits bacterial-strain-specific and time-specific antimicrobial activity. *In vitro*, it significantly reduces the growth of methicillin-sensitive *Staphylococcus aureus* (MSSA), methicillin-resistant *Staphylococcus aureus* (MRSA), Group A *Streptococcus*, and *Neisseria gonorrhoeae* within hours of exposure, demonstrating an 80-100 fold reduction in colony-forming units (CFU). PRP showed no significant antimicrobial effects against *E. coli* and *Pseudomonas*. The antimicrobial properties are thrombin concentration-dependent. Platelet-poor plasma (PPP) did not exhibit similar antimicrobial effects. *In vivo*, PRP treatment resulted in a significant reduction in bacterial colonies in bone samples and increased mineralized tissues in a spinal infection rabbit model. PRP was prepared to achieve a platelet concentration of 2 × 10^6 platelets/μL, approximately 10 times higher than whole blood, and activated using varying thrombin concentrations. These antimicrobial and wound-healing properties could potentially improve scalp health, indirectly promoting hair growth.

Androgenetic Alopecia and PRP

Androgenetic alopecia (AGA), the most common form of hair loss, is characterized by progressive miniaturization of hair follicles, driven by androgens, specifically testosterone (T) and its metabolite 5α-dihydrotestosterone (5α-DHT). The enzyme 5α-reductase converts T to DHT, making its inhibition a key therapeutic target. PRP's mechanism of action involves growth factors that can stimulate hair follicle proliferation and angiogenesis. Understanding the pathophysiology of AGA is crucial for evaluating the potential synergistic effects of combining PRP with other treatments. PRP

could potentially counteract androgen-induced follicle miniaturization by promoting hair growth and increasing the duration of the anagen phase.

Future Directions

Further research is needed to explore the direct effects of PRP on hair follicle stimulation and hair growth. Novel treatments for hair loss disorders are being pioneered, including the repurposing of existing pharmaceuticals.

Gene Therapy Approaches for Hair Regrowth

Current treatments for androgenetic alopecia (AGA), such as minoxidil, finasteride, and hair transplantation, primarily maintain or transplant existing hair follicles, failing to induce *de novo* hair follicle formation. This limitation highlights the need for therapies that stimulate new hair growth.

Dermal condensate (DC) cells are specialized dermal cells essential for hair follicle formation. Two signals, Signal X and Signal Y, are necessary and sufficient for DC formation. *In vivo* genetic activation of these signals results in DC progenitor cell proliferation and subsequent DC formation. The level and duration of these signals modulate DC size, a determinant of hair follicle size.

An *in vitro* platform has been developed to generate DC cells using Signal X and Signal Y agonists, demonstrating robust DC gene expression and expansion. Plans involve utilizing a hair graft model to assess the efficacy of Signal X and Signal Y in inducing new hair follicle formation. High-throughput screening will be employed to optimize the dose and duration of Signal X and Signal Y administration. Functional validation of DC cells to generate new hair is a critical next step, including cell culture, mouse models, FACS, qPCR, and hair reconstitution assays, with histological and molecular analysis to validate the findings.

Platelet concentrates, specifically platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), are biomaterials with regenerative potential. Platelets contain over 30 bioactive proteins, including growth factors such as platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), fibroblastic growth factor (FGF), connective tissue growth factor (CTGF), and insulin-like growth factor (IGF-1). These growth factors are crucial for hemostasis and tissue healing through the inflammatory process. Gene therapy strategies could leverage similar mechanisms by delivering genes encoding these factors or molecules to stimulate hair follicle stem cells.

PRF offers advantages over PRP, including simplified preparation, absence of biochemical manipulation, higher platelet and growth factor concentrations, greater leukocyte content, gradual growth factor release, and a stronger, more durable effect on osteoblast proliferation and differentiation. PRF's sustained release of growth factors could be a model for designing gene therapy vectors that provide prolonged expression of therapeutic genes in the scalp. Clinical trial designs involving test and control groups, along with outcome measures like visual analog scales and clinical parameters, can inform the design of clinical trials for gene therapy approaches for hair regrowth.

Androgenetic alopecia (AGA) is characterized by hair follicle miniaturization and a shortened anagen phase. The enzyme 5α-reductase, which converts testosterone to dihydrotestosterone (DHT), plays a crucial role in AGA pathogenesis, making its inhibition a primary therapeutic target. Gene therapy could potentially deliver genes that encode for proteins that inhibit 5α-reductase, offering a more targeted and sustained approach compared to traditional pharmacological

interventions. Clinical trial methodologies, such as phototrichogram analysis and pull tests, can be applied to assess the effectiveness of gene therapy interventions.

PRP injections, a technological advance, leverage concentrated growth factors to stimulate natural hair growth. PRP's success suggests the potential of growth factor-based therapies, which could inform future gene therapy approaches aimed at delivering or enhancing the production of these growth factors directly within the scalp.

Dr. Anthony Oro's research at Stanford University encompasses the engineering of functionalized tissue, including hair follicles, to treat various disorders. His work extends to investigating the potential of repurposing existing drugs for hair regrowth.

Low-level laser (light) therapy (LLLT), also known as photobiomodulation, employs low-to-mid power lasers or light-emitting diodes (LEDs) within the visible (red) or near-infrared (NIR) spectrum (600-1000 nm) to promote tissue regeneration and healing, reduce inflammation, and relieve pain. The primary mechanism of action is believed to involve mitochondrial stimulation, leading to increased ATP production and modulation of reactive oxygen species. Given LLLT's immuno-regulatory and neuroprotective properties, as well as its action on stem and progenitor cells, future research could explore the combined use of LLLT with gene therapy for hair regrowth. Gene therapy could be used to deliver growth factors or inhibit hair loss genes, while LLLT could be employed to enhance the delivery and efficacy of the gene therapy vectors, stimulate hair follicle stem cells, and reduce inflammation in the scalp.

Comparative Analysis of Treatment Effectiveness

Comparative Analysis of Treatment Effectiveness

This document presents a comparative analysis of treatment effectiveness across various medical conditions, including chronic pain, alopecia, asthma, orthopedic issues, spinal infections, and dermatological disorders. The analysis encompasses a range of therapeutic modalities, including pharmacological interventions, regenerative medicine approaches, and dietary supplements.

Chronic Pain Management

A systematic review of oral and topical nonsteroidal anti-inflammatory drugs (NSAIDs) for chronic pain (osteoarthritis, rheumatoid arthritis, soft tissue pain, back pain, and ankylosing spondylitis) revealed no statistically significant differences in short-term pain relief among oral NSAIDs, topical NSAIDs, or between oral and topical NSAIDs. However, safety profiles differed. Celecoxib presented a lower risk of cardiovascular events and gastroprotective properties compared to nonselective NSAIDs, contingent on patient factors. Nonselective NSAIDs carried similar risks of serious gastrointestinal events and, except for naproxen, comparable cardiovascular risks. Nabumetone, a partially selective NSAID, showed gastroprotective benefits over nonselective NSAIDs. Topical diclofenac offered gastroprotection compared to oral NSAIDs but increased the risk of application site dryness. Diclofenac 1.5% topical solution was associated with more application site reactions and withdrawals due to adverse events, an effect not observed with diclofenac 1.0% topical gel compared to placebo.

Alopecia

Radiation therapy-induced alopecia, a common side effect of cancer treatment, contrasts with chemotherapy-induced alopecia. Radiation-induced hair loss severity and duration depend on radiation dosage and treatment field size; higher doses can cause permanent hair loss.

Chemotherapy-induced alopecia is typically temporary, affecting the entire body. Even at lower radiation doses, hair regrowth is not guaranteed.

Platelet-rich plasma (PRP) injections are presented as a non-surgical treatment for hair loss, utilizing concentrated growth factors from the patient's blood to stimulate hair growth. A study reported a 93% regrowth beyond baseline after four months of monthly PRP injections. Underlying conditions may influence outcomes, necessitating patient history review. Maintenance injections are recommended for chronic hair loss.

A randomized, double-blind, placebo-controlled trial evaluated RJ-SP4AGA capsules (containing *Serenoa repens* and *Pygeum africanum* lipid co-extract) for androgenetic alopecia (AGA) in post-menopausal women. The RJ-SP4AGA group showed a statistically significant increase in anagen hair and a decrease in telogen hair percentages compared to placebo ($p < 0.001$) after 16 weeks. Hair resistance to traction increased in both groups. The study attributed these effects to the 5-alpha reductase inhibiting activity of *Serenoa repens* and *Pygeum africanum*, reducing dihydrotestosterone (DHT) production. *In vitro* studies showed that the active ingredient, "Complex Alphablok S," inhibited 5-alpha reductase activity by up to 68% in human scalp fibroblasts.

Current androgenetic alopecia (AGA) treatments (minoxidil, finasteride, hair transplantation) primarily maintain or transplant existing hair. An alternative strategy focuses on inducing new hair follicles by manipulating dermal condensate (DC) cells, which are specialized dermal cells essential for hair formation. Research identified signals X and Y, required and sufficient for DC formation. *In vitro* experiments showed that agonists for signals X and Y resulted in robust DC gene expression and expansion from DC progenitors.

Nutrients and natural substances are also considered for hair health. Vitamin A protects hair follicle cells from free radical damage (5,000-25,000 IU/day). Vitamin C supports collagen production (100-200 mg/day). Vitamin E maintains cell membrane integrity (50-400 IU/day). B vitamins (B1, B2, niacin, pantothenic acid) deficiencies can lead to undernourishment of hair follicle cells (25-50 mg/day). Folic acid is essential for cell division (400-800 mcg/day). Biotin is crucial for protein, fat, and carbohydrate metabolism (500-1000 mcg/day). Calcium stimulates cell mediators (100-200 mg/day), alongside magnesium. Iodine supports thyroid function (112-225 mcg/day). Zinc is essential for DNA and RNA production (15 mg/day). Selenium is necessary for iodine metabolism (25-50 mcg/day). Beta-sitosterol and saw palmetto extract (50 mg beta-sitosterol and 200 mg saw palmetto extract twice daily) demonstrated a 60% improvement rate in scalp hair growth compared to 11% in the placebo group over an average of 4.6 months. He Shou Wu, Horsetail, PABA, Choline and inositol, L-Methionine and L-cysteine, L-Lysine, and MSM are also considered.

Asthma

A Drug Effectiveness Review Project report (October 2008) analyzed quick-relief asthma medications. Efficacy analyses compared albuterol vs. levalbuterol, albuterol vs. albuterol plus ipratropium bromide, ipratropium bromide vs. ipratropium bromide plus albuterol, albuterol vs. fenoterol, albuterol vs. terbutaline, fenoterol vs. terbutaline, fenoterol vs. ipratropium bromide, fenoterol plus ipratropium bromide vs. fenoterol, and albuterol vs. pirbuterol. Safety analyses detailed adverse event profiles of albuterol vs. levalbuterol, albuterol vs. pirbuterol, and levalbuterol vs. albuterol plus ipratropium bromide. Subpopulation analyses considered age, sex, race, and comorbidities. The report acknowledged that a full update was not conducted based on the most recent scan of the medical literature.

Orthopedic Conditions

PRP therapy for orthopedic conditions has yielded variable results. Meta-analyses of human tendinopathy studies show limited evidence supporting PRP's effectiveness, except in minor rotator cuff lesions. In Achilles tendinopathy, findings are mixed; PRP clot implantation during surgical reconstruction of Achilles tendon rupture has shown improvements. Leucocyte-rich PRP showed therapeutic benefits in Achilles tendinopathy, contrasting with leucocyte-poor PRP.

In equine models, PRP showed promise in surgically induced superficial digital flexor tendon (SDFT) injuries. Clinical cases of severe mid-body suspensory desmitis in Standardbred racehorses treated with PRP demonstrated a high return-to-racing rate. PRP injections in suspensory ligament branch desmitis/sesamoiditis lesions in Thoroughbred yearlings increased the number of horses racing as 2-year-olds. PRP has also been utilized as a vehicle for allogeneic adipose-derived cells in treating clinical SDF tendinitis.

For osteoarthritis (OA) in humans, PRP has consistently outperformed hyaluronic acid or saline in managing clinical signs and dysfunction in knee OA, with effects lasting up to 12 months. The efficacy of PRP in hip OA remains less defined.

Guided Bone Regeneration

PRF as an adjunct to guided bone regeneration (GBR) procedures was investigated for soft tissue wound healing and postoperative pain. Patients receiving GBR with PRF experienced a more rapid decline in postoperative pain during the initial week. However, two patients in the PRF group exhibited membrane exposure, while no membrane exposure was observed in the control group.

Tendinopathy and Arthritis

PRP injections are utilized to treat tendinopathy and arthritis. Autologous blood injections (ABI) are presented as an alternative, often covered by insurance. Stem cell treatment is also mentioned as another possible treatment for tendinopathy and arthritis, although the UW Medicine Sports Medicine Center does not currently offer this treatment.

Spinal Infections

PRP's antimicrobial properties and efficacy as a prophylactic treatment for implant-associated spinal infections were investigated. *In vitro*, PRP reduced colony-forming units (CFU) of MSSA, MRSA, Group A *Streptococcus*, and *Neisseria gonorrhoeae*. PRP did not exhibit significant antimicrobial activity against *E. coli* and *Pseudomonas*. The antimicrobial effects were dependent on thrombin concentration. *In vivo*, PRP treatment resulted in a significant reduction in bacterial colonies in bone samples and increased mineralized tissues.

Sports and Musculoskeletal Injuries

PRP therapy is an emerging treatment for chronic sports and musculoskeletal injuries, stimulating tissue repair in damaged ligaments, tendons, and joints. Unlike corticosteroids, PRP can be safely administered to weight-bearing tendons. Clinical applications include rotator cuff injuries, shoulder pain and instability, tennis and golfer’s elbow, hamstring and hip strains, knee sprains and instability, patellofemoral syndrome and patellar tendinosis, ankle sprains, Achilles tendinosis and plantar fasciitis, knee and hip osteoarthritis, sports hernias, and other chronic tendon and ligament problems.

Dermatological Conditions

Dr. Anthony Oro's research focuses on novel therapies for dermatological conditions, including genetic disorders, cancer, and autoimmune diseases. Therapeutic Reprogramming involves converting patients' adult stem cells into induced pluripotent stem cells (iPS), correcting the disease-causing genetic code using CRISPR technology, and growing healthy cells for grafting onto damaged tissue.

Hedgehog Pathway inhibitors have been developed and FDA approved for basal cell carcinoma. Dr. Oro's group also investigates tumor resistance mechanisms. A rheumatoid arthritis drug was repurposed to treat alopecia areata.

Challenges and Future Research Needs

Permanent Supportive Housing (PSH)

While PSH effectively houses individuals experiencing homelessness and mental illness with complex needs, understanding the relationship between high-risk behaviors and housing stability remains a challenge. Existing studies offer limited insight into factors associated with housing loss, suggesting individual characteristics alone are insufficient predictors. A review identified risks to self (e.g., overdose, suicide attempts) and others (e.g., fires, violence) as prevalent in PSH. Overdose was a significant cause of death. Management approaches are categorized as clinical, relational/educational, surveillant, restrictive, strategic, design-based, legal, and self-defense. A key challenge is the lack of rigorous evaluation of these approaches' effectiveness. Some, particularly legal, restrictive, or surveillant methods, may conflict with program objectives like resident empowerment. Future research should evaluate the effectiveness of different management approaches, considering their impact on resident autonomy, housing stability, and ethical implications.

Treatment Effect Estimation

Estimating treatment effects is crucial for evaluating policies, but selection bias poses a significant challenge. This bias arises because treated individuals often differ systematically from untreated individuals. Social experiments mitigate this bias through random assignment, but most economic research relies on observational data, requiring statistical control. Regression and matching techniques address selection bias by controlling for observed covariates, relying on the assumption of conditional independence. Future research should develop more robust methods for addressing selection bias in observational studies, especially when conditional independence is questionable. This includes exploring alternative identification strategies and sensitivity analyses to assess the impact of unobserved confounders. Refining matching techniques for high-dimensional covariate spaces and incorporating prior knowledge about treatment assignment is also needed.

Selection Bias in Epidemiological Studies

Selection bias, arising when the association between exposure and health outcome differs between study participants and the target population, distorts measures of association. Key sources include selective survival, losses to follow-up, volunteer bias, non-response bias, hospital patient bias (Berkson’s bias), and the healthy worker effect. Methodologically, considering selection probabilities of exposed and unexposed cases and controls is crucial, as is accounting for differential participation or loss to follow-up in cohort studies. Future research should focus on strategies for mitigating selection bias and obtaining data from external sources when possible.

Obesity Treatment

Current obesity treatments face challenges in access, long-term maintenance, and individual responsiveness. Intensive lifestyle interventions (ILI) are effective but limited by cost, time, and availability. Remotely delivered interventions offer a cost-effective alternative, but their effectiveness is generally lower. Long-term weight maintenance is difficult due to physiological and environmental factors. Pharmacotherapy can enhance initial weight loss, but concerns over adverse effects and costs limit use. Identifying predictors of response is crucial for improving treatment matching. Pediatric obesity treatment faces barriers due to resource-intensive programs and poor insurance reimbursement. New technologies offer potential solutions, but long-term BMI decreases have not been consistently achieved. Future research should improve the reach and effectiveness of remotely delivered behavioral interventions, identify new or repurposed pharmacologic treatments, advocate for improved reimbursement policies, explore increasingly sophisticated technologies (including AI), and identify reliable predictors of treatment response.

Laboratory Risk Assessment

The Stanford Laboratory Risk Assessment Tool provides a structured framework for hazard identification and mitigation. However, its effectiveness hinges on thorough hazard identification and accurate risk rating. Future research should focus on developing more sophisticated methods for hazard identification, potentially leveraging machine learning to analyze experimental protocols and accident reports. Refining the risk rating process, exploring quantitative approaches, and investigating the long-term impact of such tools on laboratory safety culture are also needed.

Diagnostic Error

Diagnostic error is a significant problem, contributing to substantial mortality and morbidity. A key challenge lies in the historical exclusion of patient perspectives in diagnostic research. This exclusion stems from a traditional research paradigm where researchers are considered subject-matter experts and patients are viewed as subjects or beneficiaries, rather than active participants. A lack of established methods for effectively engaging patients in diagnostic research hinders patient integration as research partners. The PAIRED project revealed difficulties among patients in understanding their role in research design and challenges for Research Mentors in integrating patients' lived experiences into research ideas. Future research should focus on developing methods for effectively engaging patients in diagnostic research and integrating their lived experiences into research ideas.

Dietary Supplement Advertising Claims

Substantiating advertising claims for dietary supplements, particularly those related to hair growth, presents challenges. A central issue is the adequacy of evidence supporting express claims. The extent to which ingredient-specific studies can be extrapolated to support claims about multi-ingredient supplements targeting a general population is questionable. The evidentiary value of consumer surveys is debated, and concerns exist about fabricated testimonials. Future research should develop rigorous methodologies for evaluating the efficacy and safety of multi-ingredient supplements, establish clear guidelines for the use of consumer surveys, and explore strategies for monitoring third-party websites and affiliate marketing practices.

Substance Use Disorder (SUD) Treatment Integration

SUD treatment integration within community health centers (CHCs) faces logistical, data infrastructure, workforce, social service network, and financing challenges. A fragmented SUD treatment system exists, with rural areas lacking DATA-waivered providers. Access to high-quality services like MOUD remains inequitably distributed. Overdose rates have disproportionately increased among marginalized populations. Future research should identify and address specific barriers to integrated SUD services within CHCs, including regulatory hurdles, workflows, data infrastructure, workforce, social service networks, and financing. Further investigation is needed to determine how CHCs can effectively implement anti-stigma training, recruit a culturally responsive workforce, and engage with community-based organizations and individuals with lived experience to deliver culturally-responsive and trauma-informed interventions. Research should also explore the role of CHCs in addressing treatment disparities for communities of color, particularly in expanding access to buprenorphine and serving patients receiving methadone maintenance therapy.

Community-Based Participatory Research (CBPR) in Urban Health

Applying Community-Based Participatory Research (CBPR) to urban health research presents challenges due to its labor-intensive nature and ethical considerations. Ensuring research questions genuinely reflect community concerns is crucial, as the impetus often comes from "outside" researchers. Ongoing development of tools and protocols is needed to navigate the ethical complexities of CBPR. Future research should focus on developing best practices for implementing CBPR in urban health contexts, evaluating its long-term impact on community health outcomes, and addressing power imbalances between researchers and community partners.

Treatment Effect Heterogeneity

Estimating treatment effect heterogeneity in randomized program evaluation faces challenges. Traditional subgroup analysis is often inappropriate. Data sparsity, particularly with many treatment combinations, poses a methodological challenge. Generalizing causal effect estimates from experimental samples to target populations is also difficult. Future research should focus on developing robust and statistically sound methodologies for estimating treatment effect heterogeneity.

Radiation-Induced Alopecia

Managing hair loss (alopecia) resulting from radiation therapy presents several challenges. There is a need for research into predictive biomarkers that can identify patients at higher risk of permanent alopecia following radiation therapy. The biological mechanisms driving changes in hair texture and color upon regrowth remain unclear and warrant further investigation. Future research should explore the psychosocial impact of radiation-induced hair loss and develop targeted interventions to improve patients' quality of life. Research is needed to identify and evaluate potential radioprotective agents or targeted therapies that can selectively protect hair follicle cells from radiation damage.

NSAIDs for Chronic Pain

Discerning clinically meaningful differences in pain relief among various NSAIDs is a challenge. The long-term safety profile of NSAIDs, particularly concerning cardiovascular and gastrointestinal risks, requires further investigation. The harms associated with topical versus oral NSAIDs also need further research. Future studies could explore personalized approaches to NSAID selection based on individual characteristics. Long-term studies are needed to fully elucidate the cardiovascular and gastrointestinal effects of different NSAIDs and to identify strategies for

mitigating these risks in vulnerable populations. Future studies should investigate strategies to minimize application site reactions and compare the long-term safety and efficacy of different topical NSAID formulations.

Radiation-Induced Alopecia: Predictive Modeling and Interventions

Predictive models are needed to accurately estimate the severity and permanence of hair loss based on individual patient characteristics and radiation parameters. A deeper understanding of the molecular and cellular mechanisms underlying radiation-induced hair follicle damage is needed. Future research should evaluate the efficacy of various interventions, such as topical medications, low-level laser therapy, and stem cell therapies, in stimulating hair regrowth after radiation therapy. Studies should also investigate the effectiveness of different coping strategies and support interventions in helping patients manage the emotional distress associated with hair loss.

Platelet Rich Plasma (PRP) for Hair Loss

The multifactorial nature of hair loss presents a diagnostic challenge that requires further investigation to optimize patient selection for PRP therapy. Research is needed to identify specific patient characteristics and comorbidities that predict treatment success or failure. Further investigation into the mechanisms by which PRP stimulates hair growth, and how these mechanisms are affected by underlying conditions, is warranted. Future research should focus on determining the long-term effectiveness of PRP therapy and establishing evidence-based guidelines for maintenance treatments to ensure sustained hair regrowth.

Quick-Relief Asthma Medications

The heterogeneity of study designs and populations complicates the synthesis of evidence and limits the ability to draw definitive conclusions regarding the superiority of one agent over another. Future research should prioritize the standardization of outcome measures and the use of rigorous study designs, including randomized controlled trials with adequate sample sizes and long-term follow-up. Additionally, research is needed to evaluate the comparative effectiveness of different combinations of quick-relief medications, such as albuterol plus ipratropium bromide, in both adult and pediatric populations. Finally, further investigation into the adverse event profiles of these medications, particularly in vulnerable populations, is warranted to inform clinical decision-making and optimize patient safety.

Summary of Current and Future Treatment Landscape

The current and future treatment landscapes across various medical domains reveal a dynamic interplay between established practices and emerging innovations, all striving for improved patient outcomes.

Polycystic Ovary Syndrome (PCOS): The 2023 international guidelines emphasize lifestyle interventions as foundational for PCOS management, focusing on weight management and overall health. Pharmacological options include combined oral contraceptive pills for menstrual irregularities and hyperandrogenism, and metformin for metabolic features. Letrozole is the first-line treatment for infertility, with other options available if it fails. *In vitro* fertilization (IVF) is reserved for cases where other ovulation induction therapies are unsuccessful. Future directions prioritize increased awareness, education, integrated care models, and further research to strengthen the evidence base. Guideline translation and dissemination through multilingual resources, including the AskPCOS app, are also planned.

Cancer Survivorship Care: Survivorship Care Plans (SCPs), including treatment summaries and follow-up plans, are increasingly recognized as essential for cancer survivors. Current initiatives focus on streamlining SCP development and delivery within electronic health records (EHRs), using a Plan-Do-Study-Act (PDSA) cycle to refine the process. Future efforts involve expanding the SCP program to other disease groups, creating disease-specific templates, and providing comprehensive training. The goal is to provide patients with a comprehensive document that facilitates informed decision-making and coordinated care.

Psychotherapy: Current psychotherapy research highlights the complexity of individual responses to treatment. While evidence-based treatments like Cognitive Behavioral Therapy (CBT) have demonstrated efficacy, a multifaceted approach is needed. Future directions involve integrated and personalized treatment strategies, empowering individuals to actively participate in their treatment, and fostering a collaborative relationship between clinicians and patients. The focus is on promoting valued action and resilience, rather than solely pursuing symptom reduction.

Menopause: The treatment landscape for menopausal symptoms includes hormone therapy (HT) and over-the-counter (OTC) supplements. Hyaluronic acid vaginal gel and suppositories are non-hormonal alternatives for vaginal dryness. Dihydroepiandrosterone (DHEA) may reduce vasomotor and psychological symptoms, and improve vaginal atrophy symptoms. Caution is warranted regarding certain OTC supplements like Siberian Rhubarb due to potential side effects. Further research is needed to validate the efficacy of Rhubarb-containing products.

Treatment Effect Estimation: Estimating treatment effects, defined as the causal impact of a binary variable on an outcome of interest, is a central concern in economics and related fields. Current methodologies include social experiments, regression models, matching estimators, and instrumental variables. A primary challenge is selection bias. The potential outcomes framework provides a rigorous foundation for understanding causality and treatment effects. Future research will likely focus on refining these methodologies, particularly in the context of observational data, to improve the robustness and reliability of treatment effect estimates.

Integrated Change Therapy (ICT): Integrated Change Therapy (ICT) is a brief treatment approach designed for adults experiencing substance use and co-occurring mental health disorders. The therapeutic framework integrates several evidence-based tools and techniques, including Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Cognitive Behavioral Therapy (CBT), and strategies for treating co-occurring disorders. The program emphasizes the importance of recovery supports.

Adaptive Treatment Strategies (ATS): Adaptive treatment strategies (ATS) represent a promising approach to address the heterogeneity in patient needs and responses to treatment, particularly for chronic conditions. The design of effective ATS hinges on the selection of appropriate tailoring variables, reliable measurement of these variables, and the derivation of decision rules. Future research should focus on building a robust theoretical literature to guide the identification of tailoring variables and the development of reliable and valid indices for repeated clinical assessments.

Hair Loss in Dialysis Patients: Hair loss experienced by dialysis patients is addressed through a multi-faceted approach. The primary focus involves identifying and mitigating underlying causes, including nutritional deficiencies, thyroid dysfunction, and medication side effects. Interventions encompass dietary adjustments and pharmaceutical interventions. Symptomatic management emphasizes gentle hair care practices.

Adult History and Physical (H&P) Write-ups: This document provides a guide to comprehensive adult history and physical (H&P) write-ups, focusing on the structured collection and presentation

of patient information. It details the essential components of a thorough medical assessment, including the chief complaint, history of present illness (HPI), past medical history (PMH), family history (FH), social history (SH), review of systems (ROS), physical examination (PE), and data collection (labs, EKG).

Hair Cell Regeneration: The discovery of hair cell regeneration in avian inner ears has spurred optimism for treating hearing and balance disorders. Research has focused on understanding the regenerative process in birds, assessing the functional capabilities of the inner ear and neural pathways post-regeneration, and stimulating hair cell replacement in mammals.

Radiation-Induced Alopecia: Radiation therapy often induces alopecia within the treatment field. Current management strategies primarily focus on mitigating the psychological impact and providing supportive care. The current treatment landscape lacks definitive interventions to prevent or reverse radiation-induced alopecia, focusing instead on adaptive strategies and cosmetic solutions. Future research directions could explore targeted radioprotective agents or regenerative medicine approaches.

Permanent Supportive Housing (PSH): Permanent Supportive Housing (PSH) is recognized as a best practice intervention for individuals experiencing homelessness and mental illness. The current treatment landscape involves various approaches to managing high-risk behaviors and challenges in PSH programs. Future research priorities include addressing key evidence gaps to move towards best practices for preventing and managing high-risk behaviors and challenges in PSH.

Obesity: Currently, obesity treatment encompasses lifestyle interventions, pharmacotherapy, and bariatric surgery. Intensive lifestyle interventions (ILI) demonstrate efficacy. Pharmacotherapy can enhance initial weight loss and improve longer-term maintenance. For children and adolescents, a four-stage approach is recommended. New technologies offer potential for achieving recommended contact levels while minimizing participation burden.

Selection Bias: Selection bias is a systematic error that distorts study results. It occurs when the selection probabilities of exposed and unexposed cases and controls from the target population are differential and not proportional, or when rates of participation or loss to follow-up differ by both exposure and health outcome status in cohort studies.

Implications for Clinical Practice and Patient Care

Hair Loss Management: Platelet-Rich Plasma (PRP) injections offer a non-surgical option for hair loss, addressing its impact on self-esteem. The autologous nature of PRP minimizes the risk of allergic reactions. Clinical implementation requires patient evaluation, including medical history and exclusion criteria review. Dermatological expertise is crucial for accurate diagnosis, considering the multifactorial etiology of hair loss, potentially involving examination, lab work, and biopsies. Treatment protocols typically involve monthly injections initially, followed by maintenance injections. The procedure is performed using small needles, minimizing discomfort, and administered by board-certified dermatologists.

Tuberculosis (TB) Adverse Drug Effect (ADE) Management: Guidelines emphasize a systematic approach to identifying and managing ADEs associated with antimycobacterial agents, optimizing patient adherence and treatment outcomes. Common ADEs are categorized by type and causative agent, aiding in differential diagnosis. For dermatologic reactions, guidelines differentiate between mild and severe hypersensitivity reactions, providing a drug rechallenge protocol for identifying the causative agent. Drug desensitization protocols are outlined for situations where the causative drug cannot be discontinued, emphasizing caution and monitored conditions for severe reactions. For

nausea and vomiting, a management algorithm is provided, emphasizing ruling out other potential causes. In children, proper medication administration techniques are highlighted. Drug interactions, specifically isoniazid and tyramine-containing foods, are addressed. Considerations for drug use in pregnancy and specific management strategies for children are provided. The guidelines facilitate individualized treatment strategies, allowing clinicians to continue essential medications while minimizing the risk of recurrent ADEs. The importance of monitoring liver function tests and potential vestibular toxicity associated with aminoglycosides or capreomycin is highlighted.

Fungal Skin Infections: The reviewed literature on fungal skin infections reveals a potential education gap among pediatricians regarding less common fungal infections. Clinicians should be cognizant of the predominant local pathogens to guide optimal treatment strategies. Diagnostic accuracy can be improved by recognizing symptom clusters and the use of scalp dermoscopy. Confirmatory diagnostic tests, including potassium hydroxide (KOH) microscopy and fungal culture, are crucial. Treatment recommendations emphasize the use of oral antifungals for tinea capitis, with adjunctive therapies. For tinea corporis and cruris, topical antifungals are generally recommended. Many treatment recommendations are off-label, highlighting the need for careful consideration of safety profiles and appropriate dosing adjustments when treating pediatric patients.

Polycystic Ovary Syndrome (PCOS): The guideline emphasizes the importance of utilizing the revised Rotterdam criteria for diagnosing PCOS. Following diagnosis, the guideline advocates for a comprehensive assessment and management approach addressing reproductive, metabolic, cardiovascular, dermatologic, sleep, and psychological features. A lifelong reproductive health plan is recommended, emphasizing preconception risk factors, healthy lifestyle choices, prevention of weight gain, and fertility optimization. Given the increased risk of metabolic disorders, diabetes, cardiovascular disease, and sleep disorders in women with PCOS, screening and management are crucial. Furthermore, PCOS should be recognized as a high-risk condition during pregnancy, necessitating identification and monitoring. The guideline underscores the significantly increased prevalence of depressive and anxiety symptoms in women with PCOS, advocating for routine screening and psychological assessment and therapy when indicated. Supported healthy lifestyle interventions remain vital throughout the lifespan in PCOS, with a focus on overall health, prevention of weight gain, and weight management when necessary. Combined oral contraceptive pills are recommended as first-line treatment for menstrual irregularity and hyperandrogenism. Metformin is primarily recommended for metabolic features. For infertility, letrozole is the first-line pharmacological therapy.

Essential Fatty Acid Deficiency (EFAD): Identification of populations at risk for EFAD is paramount. Patients with gastrointestinal (GI) disorders and cystic fibrosis (CF) represent high-risk groups. Clinical scenarios necessitating fat restriction also predispose patients to EFAD. Clinicians should be cognizant of both the biochemical and physical manifestations of EFAD. Early recognition of these indicators is crucial for timely intervention and prevention of adverse outcomes.

Exertional Rhabdomyolysis (ER): This clinical practice guideline provides a framework for the assessment and management of exertional rhabdomyolysis (ER), emphasizing the importance of individualized treatment strategies. The guideline highlights the critical role of creatine kinase (CK) levels in diagnosis and monitoring. The document differentiates between outpatient and inpatient management based on the presence of high-risk markers. Recognition of risk factors is crucial for implementing preventive strategies and tailoring return-to-duty protocols. The guideline also emphasizes the importance of obtaining a detailed history of supplement use in all ER cases.

Scalp Cooling During Chemotherapy: This document emphasizes the collaborative nature of the scalp cooling procedure, delineating responsibilities between the infusion team, the patient, and

their caregiver. The document underscores the necessity of a well-fitted cap for optimal hair preservation. Furthermore, it addresses practical considerations for patient comfort during treatment. Financial aspects are clarified by directing patients to Paxman for payment-related inquiries. This guidance aims to equip patients and caregivers with the knowledge and resources necessary for effective scalp cooling, ultimately contributing to improved patient experience and potential reduction in chemotherapy-induced alopecia.

Nutrition-Focused Physical Exam (NFPE): Implementing NFPE protocols can improve the identification of malnutrition, leading to timely and appropriate nutrition interventions. The NFPE involves a systematic evaluation of physical signs indicative of malnutrition, including overall appearance, muscle loss, fat loss, and fluid status. The NFPE utilizes physical exam techniques such as inspection, palpation, percussion, and auscultation. Diagnosis requires meeting specific criteria for adults and children.

Buprenorphine for Opioid Addiction: This Treatment Improvement Protocol (TIP) offers clinical guidelines for utilizing buprenorphine in the treatment of opioid addiction. Detailed treatment protocols are provided for managing opioid withdrawal and implementing maintenance therapy with buprenorphine. Furthermore, the TIP addresses the treatment of special populations. The document also elucidates policies and procedures relevant to office-based opioid addiction treatment.

Adult History and Physical (H&P) Write-Ups: The guide underscores the need for a patient-centered approach, highlighting the inclusion of the patient's perspective, feelings, and thoughts regarding their illness within the History of Present Illness (HPI). Methodologically, the guide advocates for a chronological and organized approach to documenting the development of the chief complaint. The comprehensive nature of the H&P facilitates accurate diagnosis and treatment planning.

Hair Loss in Dialysis Patients: Hair loss during dialysis is a multifactorial issue, potentially stemming from low protein levels, vitamin deficiencies, thyroid problems, or medication side effects. A collaborative approach involving the physician, dietitian, and potentially a pharmacist is crucial for effective patient care. Clinicians should routinely monitor protein levels and vitamin status through lab work, review medication lists for potential causative agents, and consider thyroid function assessments.

Radiation-Induced Alopecia: Radiation therapy frequently induces alopecia within the treatment field. Clinical practice necessitates informing patients about the potential for hair loss, differentiating between temporary and permanent outcomes based on the planned radiation dose. Furthermore, patients should be counseled on strategies to manage hair loss. Clinicians should also discuss options such as wigs, scarves, and hats, providing resources for wig selection and care.

Survivorship Care Plans (SCPs): The implementation of Survivorship Care Plans (SCPs) within the electronic health record (EHR) demonstrates significant implications for clinical practice and patient care. The transition to an electronic format within EPIC led to substantial improvements. Qualitative feedback from providers indicated that the streamlined process facilitated more efficient SCP delivery.

Cognitive Behavioral Therapy (CBT): The principles of Cognitive Behavioral Therapy (CBT) have significant implications for clinical practice and patient care in the treatment of anxiety and depression. The program emphasizes the importance of evidence-based interventions. Clinicians should consider integrating various techniques into their practice, tailoring the specific interventions to the individual needs of each patient. The manual promotes a collaborative approach, where

clinicians and patients work together to identify and address individual challenges, fostering a sense of ownership and responsibility in the therapeutic process.

- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 41.pdf [inferred]
- [Author, A. A.]. [inferred] ([Inferred Year]). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 40.pdf
- [Author, A. A.]. [inferred] ([Publication Year inferred from filename]). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 39.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred].
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 37.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 35.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 34.pdf [inferred].
- [Author, A. A.]. [inferred]. ([Publication Year inferred from filename]). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 33.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 31.pdf [inferred]
- [Author, A. A.]. [inferred] ([Publication Year inferred from filename]). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from file 30.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 29.pdf [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 28.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Genetic and hormonal factors in androgenetic alopecia]. [inferred]. Retrieved from 27.pdf
- Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001). Nuclear hormone receptors and lipid metabolism: opening the dialogue. *Science*, *294*(5545), 1866-1870.
- Falkenstein, E., Tillmann, H. C., Christ, M., Feuring, M., & Wehling, M. (2000). Steroid hormone receptors: Two classes of transcription factors. *Pharmacological Reviews*, *52*(4), 513-556.
- Jordan, V. C. (2002). Selective estrogen receptor modulation: concept and consequences in cancer. *Cancer*, *94*(8), 2078-2085.
- Mayo, N. (n.d.). [Title of paper: Mechanism of action of existing treatments for baldness]. [inferred].
- Rosenfeld, M. G., & Glass, C. K. (2001). Coregulator codes in transcriptional control. *The Journal of Biological Chemistry*, *276*(39), 36875-36878.
- Sanchez, R., Nguyen, D., Rocha, W., White, R., & Moudgil, V. K. (2002). Heat shock protein phosphorylation and steroid receptor activation. *Annals of the New York Academy of Sciences*, *973*(1), 151-154.
- Spano, F., & Donovan, J. (2014). Frontal fibrosing alopecia: a clinical review. *Journal of the American Academy of Dermatology*, *70*(6), 1055-1063.
- Szabo, P. E., Hosszu, K. L., Strelkov, P., & Toth, G. (2012). Inter-individual variation in nuclear DNA breakdown in human hair shafts. *PloS One*, *7*(9), e46989.
- [Author, A. A.]. (n.d.). [Title of paper: Mechanism of action of existing baldness treatments] [inferred]. Retrieved from 53.pdf [inferred]

- [Author, A. A.]. (n.d.). [Title of paper: Mechanism of action of existing baldness treatments] [inferred]. Retrieved from 52.pdf [inferred]
- [Author, A. A.]. (Year). [Title of paper: Mechanism of action of existing baldness treatments] [inferred]. [inferred] Retrieved from 51.pdf [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Mechanism of action of existing baldness treatments] [inferred]. Retrieved from 50.pdf [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Mechanism of action of existing baldness treatments] [inferred]. Retrieved from 49.pdf [inferred].
- [Author, A. A.]. [inferred] ([Inferred Year]). [Title of paper: Mechanism of action of existing baldness treatments]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Mechanism of action of existing baldness treatments] [inferred]. Retrieved from 46.pdf [inferred]
- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Mechanism of action of existing baldness treatments]. [inferred]. Retrieved from 44.pdf
- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Mechanism of action of existing baldness treatments]. [inferred]. Retrieved from 43.pdf
- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Mechanism of action of existing baldness treatments]. [inferred].
- [Author, A. A.]. (Year, inferred). [Title of paper: Mechanism of action of existing baldness treatments] [inferred].
- [Author, A. A.]. [inferred] ([Publication Year inferred from arXiv ID]). [Title of paper: Mechanism of action of existing baldness treatments]. [inferred].
- [Author, A. A.]. [inferred] ([Publication Year inferred from arXiv ID]). [Title of paper: Mechanism of action of existing baldness treatments]. [inferred]. Retrieved from 39.pdf
- Lambert Academy Publisher. (2020). *The follicular unit extraction (FUE) technique of hair transplantation*.
- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred]. Retrieved from 56.pdf [inferred]
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Current treatment options: Efficacy and limitations; Surgical options: Hair transplantation techniques]. [inferred] (57.pdf).
- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred]. Retrieved from 58.pdf [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred].
- [Author, A. A.]. [inferred]. ([Publication Year inferred from filename]). [Title of paper: Current treatment options: Efficacy and limitations of surgical options: Hair transplantation techniques]. [inferred]. Retrieved from 62.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Surgical Options: Hair Transplantation Techniques]. [inferred]. Retrieved from 63.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred]. Retrieved from 65.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred]. Retrieved from 66.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred]. Retrieved from 67.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Current treatment options: Efficacy and limitations of surgical options: Hair transplantation techniques]. [inferred].

- [Author, A. A.]. (n.d.). [Title of paper: Surgical options: Hair transplantation techniques]. [inferred]. Retrieved from 70.pdf [inferred]
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred]. Retrieved from 74.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred].
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred]. Retrieved from 72.pdf
- [Author, A. A.]. (Year). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred].
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred]. Retrieved from 70.pdf
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred]. Retrieved from 69.pdf
- [Author, A. A.]. (Year). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred]. Retrieved from 65.pdf
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred]. Retrieved from 63.pdf
- [Author, A. A.]. [inferred] ([inferred year]). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred]. Retrieved from 62.pdf [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred].
- [Author, A. A.]. (Year). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred]. Retrieved from file 60.pdf [inferred]
- Patankar, M. S., et al. (2019). [Title of paper: Stem cell therapy and regenerative medicine]. [inferred].
- Busetto, R., Cavalieri, E., Zanoni, M., Facchin, F., Pavan, A., Pizzi, M., ... & Tagliafico, E. (2019). Stem cell therapy and regenerative medicine: Emerging approaches in urology. *World Journal of Stem Cells, 11*(11), 952-964. https://doi.org/10.4252/wjsc.v11.i11.952
- Opoku-Acheampong, K., et al. (2013). [Title of paper on stem cell therapy and regenerative medicine]. [Inferred].
- [Author, A. A.]. [inferred] ([Inferred Year]). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred]. Retrieved from 81.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss: Emerging Therapies and Future Directions]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-rich plasma (PRP) therapy for hair loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].

- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Platelet-Rich Plasma (PRP) Therapy for Hair Loss]. [inferred].
- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Gene therapy approaches for hair regrowth]. [inferred]. Retrieved from 82.pdf
- [Author, A. A.]. (Year [inferred]). [Title of paper: Gene therapy approaches for hair regrowth] [inferred]. Retrieved from 81.pdf
- [Author, A. A.]. (Year, inferred). [Title of paper: Gene therapy approaches for hair regrowth]. [inferred]
- [Author, A. A.]. (Year [inferred]). [Title of paper: Gene therapy approaches for hair regrowth] [inferred]. *[Journal Title or Source]* [inferred]. Retrieved from 79.pdf
- [Author, A. A.]. (Year, inferred). [Title of paper: Gene therapy approaches for hair regrowth] [inferred]. Retrieved from 78.pdf
- [Author, A. A.]. (Year [inferred]). [Title of paper: Gene therapy approaches for hair regrowth] [inferred]. Retrieved from 77.pdf
- [Author, A. A.]. [inferred] ([Publication Year inferred from arXiv ID]). [Title of paper: Gene therapy approaches for hair regrowth]. [inferred]. Retrieved from 76.pdf
- [Author, A. A.]. (Year [inferred]). [Title of paper: Gene therapy approaches for hair regrowth] [inferred]. *[Journal Name]* [inferred], *[Volume]* [inferred], [Pages] [inferred]. (Original work published [inferred from 75.pdf, likely 2075 if interpreted as year])
- [Author, A. A.]. (Year [inferred]). [Title of paper: Gene therapy approaches for hair regrowth] [inferred]. Retrieved from 74.pdf
- [Author, A. A.]. (Year [inferred]). [Title of paper: Gene therapy approaches for hair regrowth] [inferred]. Retrieved from 73.pdf
- [Author, A. A.]. [inferred] ([Inferred Year]). [Title of paper: Gene therapy approaches for hair regrowth]. [inferred]. Retrieved from 72.pdf
- [Author, A. A.]. (Year [inferred]). [Title of paper: Gene therapy approaches for hair regrowth] [inferred]. Retrieved from 71.pdf
- [Author, A. A.]. (Year, inferred). [Title of paper: Gene therapy approaches for hair regrowth] [inferred].
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Gene therapy approaches for hair regrowth]. [inferred]. Retrieved from 69.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]. Retrieved from 88.pdf [inferred]
- [Author, A. A.]. [inferred] ([Inferred Year]). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]. Retrieved from 87.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]. Retrieved from 86.pdf [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]. Retrieved from 85.pdf [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]

- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]. Retrieved from 83.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Comparative Analysis of Treatment Effectiveness]. [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]. Retrieved from 79.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]. Retrieved from 78.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Comparative analysis of treatment effectiveness]. [inferred]. Retrieved from 74.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Challenges and future research needs in discussion]. [inferred]
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Challenges and future research needs in discussion]. [inferred]. Retrieved from 98.pdf
- [Author, A. A.]. (Year inferred). [Title of paper: Challenges and future research needs in discussion]. [inferred]
- [Author, A. A.]. (YYYY). [Title of paper: Challenges and future research needs in discussion]. [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Challenges and future research needs in discussion]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Challenges and future research needs in discussion]. [inferred]
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Challenges and future research needs in discussion]. [inferred]. Retrieved from 93.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Challenges and future research needs in discussion]. [inferred].
- [Author, A. A.]. (Year [inferred]). [Title of paper: Challenges and future research needs in discussion]. [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Challenges and future research needs in discussion]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Challenges and future research needs in discussion]. [inferred]. Retrieved from 89.pdf
- [Author, A. A.]. (Year). [Title of paper]. [inferred]. [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Challenges and future research needs in discussion]. [inferred].
- [Author, A. A.]. [inferred] ([Publication Year, inferred]). [Title of paper: Challenges and future research needs in discussion]. [inferred]. Retrieved from 86.pdf
- [Author, A. A.]. (Year [inferred]). [Title of paper: Challenges and future research needs in discussion]. [inferred]. Retrieved from 85.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Summary of current and future treatment landscape]. [inferred] Retrieved from 110.pdf

- [Author, A. A.]. [inferred] ([Publication Year inferred from 109.pdf]). [Title of paper: Summary of current and future treatment landscape]. [inferred]. Retrieved from 109.pdf
- [Author, A. A.]. (2024). [Title of paper: Summary of current and future treatment landscape]. [inferred]. (Original work published 2024). Retrieved from 108.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Summary of current and future treatment landscape]. [inferred]. Retrieved from 107.pdf.
- [Author, A. A.]. (n.d.). [Title of paper: Summary of current and future treatment landscape]. [inferred].
- [Author, A. A.]. (2024). [Title of paper: Summary of current and future treatment landscape]. [inferred]. (Original work published 2005). Retrieved from 105.pdf [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Summary of current and future treatment landscape]. [inferred]. Retrieved from 104.pdf [inferred].
- [Author, A. A.]. (2024). [Title of paper: Summary of current and future treatment landscape]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Summary of current and future treatment landscape]. [inferred]. Retrieved from 102.pdf [inferred].
- [Author, A. A.]. (Year). [Title of paper]. [inferred] [inferred from 101.pdf file name]
- [Author, A. A.]. (n.d.). [Title of paper: Summary of current and future treatment landscape]. [inferred]
- [Author, A. A.]. (2099). [Title of paper: Summary of current and future treatment landscape]. [inferred]
- [Author, A. A.]. [inferred] ([Publication Year inferred from arXiv ID]). [Title of paper: Summary of current and future treatment landscape]. [inferred]. Retrieved from 98.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Summary of current and future treatment landscape]. [inferred]. Retrieved from 97.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Summary of current and future treatment landscape]. [inferred] Retrieved from 96.pdf
- [Author, A. A.]. (YYYY). [Title of paper: Implications for clinical practice and patient care]. [inferred].
- [Author, A. A.]. [inferred] ([Publication Year inferred from 121.pdf]). [Title of paper: Implications for clinical practice and patient care]. [inferred]. Retrieved from 121.pdf
- [Author, A. A.]. [inferred] ([Publication Year inferred from 120.pdf]). [Title of paper related to implications for clinical practice and patient care]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Implications for clinical practice and patient care]. [inferred].
- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Implications for clinical practice and patient care]. [inferred]. Retrieved from 118.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Implications for clinical practice and patient care]. [inferred]
- [Author, A. A.]. (n.d.). [Title of paper: Implications for clinical practice and patient care]. [inferred].
- [Author, A. A.]. (n.d.). [Title of paper: Implications for clinical practice and patient care]. [inferred]
- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Implications for clinical practice and patient care]. [inferred]. Retrieved from 114.pdf
- [Author, A. A.]. (n.d.). [Title of paper: Implications for clinical practice and patient care]. [inferred]
- [Author, A. A.]. (Year [inferred]). [Title of paper: Implications for clinical practice and patient care]. [inferred] Retrieved from 112.pdf
- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Implications for clinical practice and patient care]. [inferred]. Retrieved from 111.pdf

- [Author, A. A.]. (YYYY). [Title of paper: Implications for clinical practice and patient care]. [inferred].
- [Author, A. A.]. [inferred]. ([Publication Year, inferred]). [Title of paper: Implications for clinical practice and patient care]. [inferred]. Retrieved from 109.pdf
- [Author, A. A.]. (Year [inferred]). [Title of paper: Implications for clinical practice and patient care]. [inferred]

References

1. 49.pdf
2. 61.pdf
3. 75.pdf
4. 74.pdf
5. 60.pdf
6. 48.pdf
7. 89.pdf
8. 76.pdf
9. 62.pdf
10. 63.pdf
11. 77.pdf
12. 88.pdf
13. 98.pdf
14. 73.pdf
15. 67.pdf
16. 9.pdf
17. 8.pdf
18. 66.pdf
19. 72.pdf
20. 99.pdf
21. 64.pdf
22. 70.pdf
23. 58.pdf

24. 59.pdf
25. 71.pdf
26. 65.pdf
27. 103.pdf
28. 117.pdf
29. 16.pdf
30. 17.pdf
31. 116.pdf
32. 102.pdf
33. 114.pdf
34. 100.pdf
35. 29.pdf
36. 15.pdf
37. 14.pdf
38. 28.pdf
39. 101.pdf
40. 115.pdf
41. 111.pdf
42. 105.pdf
43. 10.pdf
44. 38.pdf
45. 39.pdf
46. 11.pdf
47. 104.pdf
48. 110.pdf
49. 106.pdf
50. 112.pdf
51. 13.pdf

52. 12.pdf
53. 113.pdf
54. 107.pdf
55. 122.pdf
56. 23.pdf
57. 37.pdf
58. 36.pdf
59. 22.pdf
60. 121.pdf
61. 109.pdf
62. 34.pdf
63. 20.pdf
64. 21.pdf
65. 35.pdf
66. 108.pdf
67. 120.pdf
68. 118.pdf
69. 31.pdf
70. 25.pdf
71. 19.pdf
72. 18.pdf
73. 24.pdf
74. 30.pdf
75. 119.pdf
76. 26.pdf
77. 32.pdf
78. 33.pdf
79. 27.pdf

80. 83.pdf
81. 97.pdf
82. 68.pdf
83. 40.pdf
84. 54.pdf
85. 6.pdf
86. 55.pdf
87. 7.pdf
88. 41.pdf
89. 69.pdf
90. 96.pdf
91. 82.pdf
92. 94.pdf
93. 80.pdf
94. 5.pdf
95. 57.pdf
96. 43.pdf
97. 42.pdf
98. 4.pdf
99. 56.pdf
100. 81.pdf
101. 95.pdf
102. 91.pdf
103. 85.pdf
104. 52.pdf
105. 46.pdf
106. 47.pdf
107. 53.pdf

108. 1.pdf

109. 84.pdf

110. 90.pdf

111. 86.pdf

112. 92.pdf

113. 45.pdf

114. 3.pdf

115. 51.pdf

116. 79.pdf

117. 78.pdf

118. 2.pdf

119. 50.pdf

120. 44.pdf

121. 93.pdf

122. 87.pdf